Clinical characteristics of patients with severe COVID-19 who underwent dilated eye examinations
| Measure | Total (N=18) |
|---|---|
| Age, median (IQR), years | 62.5 (12) |
| Male, N (%) | 9 (50) |
| Hypertension*, N (%) | 12 (66.7) |
| Diabetes mellitus*, N (%) | 9 (50) |
| Time between confirmatory exam and dilated eye examination, median (IQR), days | 11.5 (8) |
| ICU stay, N (%) | 17 (94.4) |
| Invasive mechanical ventilation, N (%) | 14 (77.8) |
| Vasoactive pharmacological support, N (%) | 8 (44.4) |
| Any anticoagulation therapy, N (%) | 15 (83.3) |
| Prophylactic anticoagulation therapy†, N (%) | 8 (44.4) |
| Full-intensity anticoagulation therapy‡, N (%) | 7 (38.9) |
*Previously referred diagnosis described on medical records.
†Prescription of enoxaparin 40 mg/day.
‡Prescription of enoxaparin 1 mg/kg two times per day or unfractionated heparin in a dosage adjusted to activated partial thromboplastin time between 61 and 85 s.
ICU, intensive care unit.